Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > PTCT PTC Therapeutics > Detailed Quotes

PTCT PTC Therapeutics

50.200
-0.150-0.30%
Close 09/30 16:00 ET
50.2000.0000.00%
Post Mkt Price 09/30 16:01 ET
High
52.320
Open
50.230
Turnover
38.15M
Low
49.900
Pre Close
50.350
Volume
753.01K
Market Cap
3.59B
P/E(TTM)
Loss
52wk High
55.580
Shares
71.54M
P/E(Static)
Loss
52wk Low
25.010
Float Cap
3.24B
Bid/Ask %
0.00%
Historical High
78.720
Shs Float
64.45M
Volume Ratio
1.61
Historical Low
4.030
Dividend TTM
--
Div Yield TTM
--
P/B
-19.71
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
1.17%
Amplitude
4.81%
Avg Price
50.667
Lot Size
1
Float Cap
3.24B
Bid/Ask %
0.00%
Historical High
78.720
Shs Float
64.45M
Volume Ratio
1.61
Historical Low
4.030
Dividend TTM
--
P/B
-19.71
Dividend LFY
--
Turnover Ratio
1.17%
Amplitude
4.81%
Avg Price
50.667
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The firm's portfolio includes Translarna, Emflaza, Tegsedi, Waylivra, and Evrysdi. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.
CEO: Dr. Stuart W. Peltz, PhD
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...